Indaptus Therapeutics, INC 10-Q quarterly reports

Indaptus Therapeutics reports substantial net losses and cash burn, while pivoting strategy to explore acquisitions and research collaborations, raising going concern doubts.

Indaptus Therapeutics reports a significant decrease in R&D expenses and a net loss for Q1 2026, while exploring strategic transaction opportunities.

Indaptus Therapeutics reported an increased net loss for the nine months ended September 30, 2025, while advancing its Decoy20 clinical trials and raising significant capital to extend its cash runway into the first quarter of 2026.

Indaptus Therapeutics reports increased net losses and significant cash burn, raising substantial doubt about its ability to continue as a going concern, despite advancing its Decoy20 clinical program.

Indaptus Therapeutics announces its Q1 2025 financial results, detailing progress in its Phase 1 clinical trial for Decoy20 and the initiation of a combination study with Tislelizumab.

Indaptus Therapeutics reported its Q3 2024 financial results, highlighting ongoing clinical trials and a new collaboration, but also expressing substantial doubt about its ability to continue as a going concern.

Indaptus Therapeutics reports a net loss of $7.8 million for the first half of 2024, while progressing its Phase 1 clinical trial for Decoy20.

Indaptus Therapeutics reported a net loss of $3.8 million for the first quarter of 2024, while advancing its Phase 1 clinical trial for Decoy20.